AIM ImmunoTech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AIM American 2834 https://aimimmuno.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc

AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference - May 19th, 2022 12:00 pm
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program - May 18th, 2022 12:00 pm
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update - May 16th, 2022 11:05 am
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022 - May 12th, 2022 12:05 pm
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies - Apr 21st, 2022 12:05 pm
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer - Apr 12th, 2022 11:47 am
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting - Apr 11th, 2022 1:20 pm
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver - Apr 11th, 2022 11:05 am
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer - Apr 11th, 2022 11:05 am
AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Mar 31st, 2022 8:05 pm
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress - Mar 28th, 2022 11:35 am
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting - Mar 24th, 2022 2:10 pm
AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest - Mar 23rd, 2022 12:05 pm
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer - Mar 16th, 2022 11:05 am
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting - Mar 9th, 2022 12:35 pm
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer - Mar 9th, 2022 12:25 pm
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting - Mar 9th, 2022 12:05 pm
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer - Mar 8th, 2022 6:59 pm
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline - Mar 7th, 2022 1:05 pm
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer - Mar 3rd, 2022 1:35 pm